Stat Med

• 

  Publication Venue For

  • On the robustness of latent class models for diagnostic testing with no gold standard..  40:4751-4763. 2021
  • Rejoinder to "On the robustness of latent class models for diagnostic testing with no gold standard"..  40:4770-4771. 2021
  • Propensity score weighting for causal subgroup analysis..  40:4294-4309. 2021
  • Sample size re-estimation in clinical trials. 2021
  • Bayesian hierarchical models for high-dimensional mediation analysis with coordinated selection of correlated mediators. 2021
  • On the design and the analysis of stratified biomarker trials in the presence of measurement error..  40:2783-2799. 2021
  • Bias testing, bias correction, and confounder selection using an instrumental variable model..  39:4386-4404. 2020
  • Sample size requirements for detecting treatment effect heterogeneity in cluster randomized trials..  39:4218-4237. 2020
  • Regression with a right-censored predictor using inverse probability weighting methods..  39:4001-4015. 2020
  • Sample size calculation for cluster randomization trials with a time-to-event endpoint..  39:3608-3623. 2020
  • Empirical use of causal inference methods to evaluate survival differences in a real-world registry vs those found in randomized clinical trials..  39:3003-3021. 2020
  • Secondary analysis of case-control association studies: Insights on weighting-based inference motivate a new specification test..  39:2869-2882. 2020
  • Predictive accuracy of markers or risk scores for interval censored survival data..  39:2437-2446. 2020
  • Matching with time-dependent treatments: A review and look forward..  39:2350-2370. 2020
  • Dynamic prediction of Alzheimer's disease progression using features of multiple longitudinal outcomes and time-to-event data..  38:4804-4818. 2019
  • Measures for evaluation of prognostic improvement under multivariate normality for nested and nonnested models..  38:3817-3831. 2019
  • Partitioning of time trends in prevalence and mortality of lung cancer..  38:3184-3203. 2019
  • A Bayesian approach for individual-level drug benefit-risk assessment..  38:3040-3052. 2019
  • Statistical methods for building better biomarkers of chronic kidney disease..  38:1903-1917. 2019
  • Estimating the association between blood pressure variability and cardiovascular disease: An application using the ARIC Study..  38:1855-1868. 2019
  • Single-number summary and decision analytic measures can happily coexist..  38:499-500. 2019
  • Auxiliary variable-enriched biomarker-stratified design..  37:4610-4635. 2018
  • Sample size calculation for studies with grouped survival data..  37:3904-3917. 2018
  • Authors' response to comments..  36:4511-4513. 2017
  • Discrimination slope and integrated discrimination improvement - properties, relationships and impact of calibration..  36:4482-4490. 2017
  • Net reclassification index at event rate: properties and relationships..  36:4455-4467. 2017
  • An evaluation of constrained randomization for the design and analysis of group-randomized trials with binary outcomes..  36:3791-3806. 2017
  • Functional joint model for longitudinal and time-to-event data: an application to Alzheimer's disease..  36:3560-3572. 2017
  • Asymptotic distribution of ∆AUC, NRIs, and IDI based on theory of U-statistics..  36:3334-3360. 2017
  • Multidimensional latent trait linear mixed model: an application in clinical studies with multivariate longitudinal outcomes..  36:3244-3256. 2017
  • On assessing bioequivalence and interchangeability between generics based on indirect comparisons..  36:2978-2993. 2017
  • Comparison of adaptive treatment strategies based on longitudinal outcomes in sequential multiple assignment randomized trials..  36:403-415. 2017
  • Comments on 'Estimands in clinical trials - broadening the perspective'..  36:24-26. 2017
  • Methods for assessing the reliability of quality of life based on SF-36..  35:5656-5665. 2016
  • Modeling zero-modified count and semicontinuous data in health services research Part 1: background and overview..  35:5070-5093. 2016
  • Modeling zero-modified count and semicontinuous data in health services research part 2: case studies..  35:5094-5112. 2016
  • Use of the landmark method to address immortal person-time bias in comparative effectiveness research: a simulation study..  35:4824-4836. 2016
  • Robust analysis of secondary phenotypes in case-control genetic association studies..  35:4226-4237. 2016
  • Assessing agreement with relative area under the coverage probability curve..  35:3153-3165. 2016
  • An evaluation of constrained randomization for the design and analysis of group-randomized trials..  35:1565-1579. 2016
  • Using pilot data to size a two-arm randomized trial to find a nearly optimal personalized treatment strategy..  35:1245-1256. 2016
  • Numeric score-based conditional and overall change-in-status indices for ordered categorical data..  34:3622-3636. 2015
  • Scan-stratified case-control sampling for modeling blood-brain barrier integrity in multiple sclerosis..  34:2872-2880. 2015
  • Comparison of operational characteristics for binary tests with clustered data..  34:2325-2333. 2015
  • Power and sample size calculations for the Wilcoxon-Mann-Whitney test in the presence of death-censored observations..  34:406-431. 2015
  • A marginalized two-part model for semicontinuous data..  33:4891-4903. 2014
  • What to expect from net reclassification improvement with three categories..  33:4975-4987. 2014
  • Bayesian hierarchical model for multiple repeated measures and survival data: an application to Parkinson's disease..  33:4279-4291. 2014
  • How to interpret a small increase in AUC with an additional risk prediction marker: decision analysis comes through..  33:3946-3959. 2014
  • Net reclassification improvement and integrated discrimination improvement require calibrated models: relevance from a marker and model perspective..  33:3415-3418. 2014
  • Adjusting for misclassification in a stratified biomarker clinical trial..  33:3100-3113. 2014
  • Assessing the incremental predictive performance of novel biomarkers over standard predictors..  33:2577-2584. 2014
  • Joint model for a diagnostic test without a gold standard in the presence of a dependent terminal event..  33:2554-2566. 2014
  • Phase II clinical trials with time-to-event endpoints: optimal two-stage designs with one-sample log-rank test..  33:2004-2016. 2014
  • A global logrank test for adaptive treatment strategies based on observational studies..  33:760-771. 2014
  • A Bayesian approach to joint analysis of multivariate longitudinal data and parametric accelerated failure time..  33:580-594. 2014
  • Incidence estimation using a single cross-sectional age-specific prevalence survey with differential mortality..  33:422-435. 2014
  • Joint analysis of stochastic processes with application to smoking patterns and insomnia..  32:5133-5144. 2013
  • A hybrid method in combining treatment effects from matched and unmatched studies..  32:4924-4937. 2013
  • On model specification and selection of the Cox proportional hazards model..  32:4609-4623. 2013
  • Designs for randomized phase II clinical trials with two treatment arms..  32:4367-4379. 2013
  • Impact of correlation on predictive ability of biomarkers..  32:4196-4210. 2013
  • Robust Bayesian inference for multivariate longitudinal data by using normal/independent distributions..  32:3812-3828. 2013
  • Reply to taguri and matsuyama..  32:3592-3593. 2013
  • A repeated measures model for analysis of continuous outcomes in sequential parallel comparison design studies..  32:2767-2789. 2013
  • A Bayesian model for misclassified binary outcomes and correlated survival data with applications to breast cancer..  32:2320-2334. 2013
  • An information criterion for marginal structural models..  32:1383-1393. 2013
  • An adapted F-test for homogeneity of variability in follow-on biological products..  32:415-423. 2013
  • Application of the parallel line assay to assessment of biosimilar products based on binary endpoints..  32:449-461. 2013
  • Assessing biosimilarity and interchangeability of biosimilar products..  32:361-363. 2013
  • Comments on the FDA draft guidance on biosimilar products..  32:364-369. 2013
  • Impact of variability on the choice of biosimilarity limits in assessing follow-on biologics..  32:424-433. 2013
  • On the interchangeability of biologic drug products..  32:434-441. 2013
  • Scientific considerations for assessing biosimilar products..  32:370-381. 2013
  • Statistical assessment of biosimilarity based on relative distance between follow-on biologics..  32:382-392. 2013
  • Statistical methods for assessing interchangeability of biosimilars..  32:442-448. 2013
  • The evaluation of biosimilarity index based on reproducibility probability for assessing follow-on biologics..  32:406-414. 2013
  • A comparison of least squares and conditional maximum likelihood estimators under volume endpoint censoring in tumor growth experiments..  31:4061-4073. 2012
  • Adverse subpopulation regression for multivariate outcomes with high-dimensional predictors..  31:4102-4113. 2012
  • Variable selection for covariate-adjusted semiparametric inference in randomized clinical trials..  31:3789-3804. 2012
  • Misuse of DeLong test to compare AUCs for nested models..  31:2577-2587. 2012
  • A new permutation-based method for assessing agreement between two observers making replicated quantitative readings..  31:2249-2261. 2012
  • Designing a pilot sequential multiple assignment randomized trial for developing an adaptive treatment strategy..  31:1887-1902. 2012
  • Bayesian semiparametric regression models for evaluating pathway effects on continuous and binary clinical outcomes..  31:1633-1651. 2012
  • Quantifying discrimination of Framingham risk functions with different survival C statistics..  31:1543-1553. 2012
  • A framework for quantifying net benefits of alternative prognostic models..  31:114-130. 2012
  • Estimation and testing of the relative risk of disease in case-control studies with a set of k matched controls per case with known prevalence of disease..  31:29-44. 2012
  • Assessing agreement with repeated measures for random observers..  30:3546-3559. 2011
  • Evaluation metrics for biostatistical and epidemiological collaborations..  30:2767-2777. 2011
  • A Bayesian growth mixture model to examine maternal hypertension and birth outcomes..  30:2721-2735. 2011
  • A min-max combination of biomarkers to improve diagnostic accuracy..  30:2005-2014. 2011
  • Multiple testing of treatment-effect-modifying biomarkers in a randomized clinical trial with a survival endpoint..  30:1502-1518. 2011
  • Equivalence of improvement in area under ROC curve and linear discriminant analysis coefficient under assumption of normality..  30:1410-1418. 2011
  • A new permutation-based method for assessing agreement between two observers making replicated binary readings..  30:839-853. 2011
  • Sample size calculations for evaluating a diagnostic test when the gold standard is missing at random..  30:200. 2011
  • Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers..  30:11-21. 2011
  • Analysis of multi-arm tumor growth trials in xenograft animals using phase change adaptive piecewise quadratic models..  29:2399-2409. 2010
  • Using Testlet Response Theory to analyze data from a survey of attitude change among breast cancer survivors..  29:2028-2044. 2010
  • Sample size calculations for evaluating a diagnostic test when the gold standard is missing at random..  29:1572-1579. 2010
  • Strategies for analyzing multilevel cluster-randomized studies with binary outcomes collected at varying intervals of time..  27:6055-6071. 2008